Breaking AI & Tech News Analyzed

Benin’s presidential contest is tilting decisively toward the incumbent government’s nominee, Romuald Wadagni, after his only challenger, Paul Hounkpe of the Cowry Forces for an Emerging Benin party, publicly acknowledged defeat on national television. Hounkpe’s concession, aired on Monday, included a call for “republican congratulations” and a reminder that democratic health depends on mutual respect across partisan lines, as reported by AFP. Currently serving as foreign minister, Wadagni is the designated successor of President Patrice Talon, who is stepping down after two consecutive five‑year terms. The election follows a turbulent period marked by a foiled coup in late 2025, which was suppressed with the aid of Nigerian forces. Out of an electorate of nearly 8 million eligible voters, early voting proceeded at a modest pace, according to Al Jazeera correspondent Ahmed Idris reporting from Cotonou. Hounkpe’s campaign highlighted that despite a robust 7.5% GDP growth in 2024, the benefits have not sufficiently improved living standards, pointing to persistent poverty rates exceeding 30% and limited trickle‑down of economic gains. In contrast, Wadagni pledged to focus on essential services such as water access, expanded social security, and improved healthcare, positioning himself as a continuity candidate for the ruling coalition. The finance minister, who previously led the polls, was widely expected to prevail after the main opposition party, the Democrats, failed to nominate a candidate and declined to endorse Hounkpe. The Democrats also fell short of the 20% threshold needed for parliamentary representation in the January 2026 elections, securing only about 16% of the vote. Security concerns loom large for the incoming administration. The northern region continues to grapple with insurgent activity from the al‑Qaeda affiliate Jama’at Nusrat al‑Islam wal‑Muslimin (JNIM), which has inflicted heavy casualties on the military, including an attack last year that killed 54 soldiers and another incident in March that claimed 15 lives. These challenges are compounded by broader instability across the Sahel, where a succession of coups in neighboring states such as Burkina Faso, Niger, and Mali has heightened regional volatility. While Wadagni’s ascent promises policy continuity, the new president will need to address both the security vacuum in the north and the socioeconomic gap that leaves a third of Benin’s population in poverty despite recent economic growth.

The UK's housing crisis has reached a critical point, with homelessness rates among over-55s on the rise. The current housing system is failing to provide affordable options, leading to a growing number of people relying on friends and family for a roof. The issue is not just about the number of homes being built, but also about the type of housing being constructed. Currently, four-bedroom detached houses on car-dependent estates are being prioritized, which do little to address the needs of those facing rising rents and insecure tenancies. To address this crisis, there is a pressing need for genuinely affordable social housing within existing towns and cities. This means building accessible, energy-efficient homes close to shops, healthcare, green spaces, and public transport. Local authorities and housing organizations have long argued for urban densification, but planning policy still favors sprawl. The financial implications of inaction are stark. By 2029-30, local councils across England are projected to spend almost £4bn annually on temporary accommodation for those experiencing homelessness. Meanwhile, the building of new social housing, a key solution to the issue, is at historic lows. The government's intention to invest in affordable housing is welcome, but it will only deliver 300,000 new homes over a 10-year period, while there are currently 1.34m households on local authority waiting lists. To address this crisis, local councils, central government, and civil society must come together to devise an exit strategy that transforms the skyrocketing temporary accommodation bill into long-term investment in permanent social housing stock.

Metabolic liver disease, or MASLD, is projected to affect 1.8 billion people worldwide by 2050, according to a recent study. This significant increase is primarily driven by rising obesity and blood sugar levels globally.MASLD, previously known as non-alcoholic fatty liver disease (NAFLD), is one of the most prevalent and rapidly growing liver conditions worldwide. The condition's prevalence has already seen a 143% increase in just three decades, from 500 million people in 1990 to 1.3 billion people in 2023.The study, published in the Lancet Gastroenterology & Hepatology journal, highlights that high blood sugar is the leading driver of MASLD-related health problems globally, followed by high BMI and smoking. These factors are strongly linked to type 2 diabetes and obesity.Regional disparities exist, with north Africa and the Middle East having disproportionately higher rates of MASLD. However, there have been sharp increases in the number of people affected in countries across the world, including the UK, Australia, and the United States.Despite the growing number of cases, the overall impact on health has remained stable, suggesting that advances in treatment and care are helping people live longer and healthier lives. However, the increasing number of cases still poses a risk of serious complications such as liver cirrhosis or cancer in the future.

For the first time, thousands of cancer patients from Black and minority ethnic backgrounds will benefit from an enhanced genetic test offered by the NHS. The new screening expands the panel of DPYD gene variants from four to five, directly addressing a long‑standing bias that left non‑white patients vulnerable to dangerous chemotherapy side‑effects. In England, patients slated for chemotherapy undergo a genetic check that can guide dose adjustments and mitigate adverse reactions such as mouth sores, hair loss, nausea, fatigue, and, in severe cases, death. Up to 40% of the 38,000 individuals receiving fluoropyrimidine‑based chemotherapy each year experience a harmful drug reaction. Previously, the test only targeted four DPYD variants common in people of European descent, meaning many Black patients received inaccurate “all‑clear” results. The addition of a fifth variant—more prevalent among African, Caribbean and other minority groups—means clinicians can now identify patients at risk who were previously missed. Since its rollout at Manchester University NHS Foundation Trust last September, three minority‑ethnic patients have had their initial chemotherapy doses adjusted, lowering their chance of a potentially fatal reaction. Dr Veline L’Esperance, senior clinical adviser at the NHS Race and Health Observatory, called the change “tangible results for patients who have historically been left behind.” She emphasized that the update shifts the discussion on ethnic health inequality from rhetoric to actionable care. Prof Habib Naqvi, chief executive of the NHS Race and Health Observatory, described the development as a “groundbreaking outcome” for chemotherapy safety, while noting that ethnic minorities remain under‑represented in genomic research and biobanks. He warned that broader inclusion is essential for the promised benefits of precision medicine to reach all communities. Prof Dame Sue Hill, chief scientific officer for NHS England, highlighted the significance of discovering the fifth variant: “Personalising chemotherapy based on genetics can save lives and reduce harmful side‑effects, especially for patients of African ancestry.” She added that the North West NHS Genomic Medicine Service has already demonstrated the practical impact of this approach. These steps come amid broader evidence that minority patients in the UK face longer diagnostic waits, more GP visits before a cancer diagnosis, and lower perceived support during treatment. The expanded DPYD test represents a concrete effort to close those gaps and ensure equitable, science‑driven care for all cancer patients.

A comprehensive study from Denmark has concluded that taking acetaminophen, commonly known as Tylenol, during pregnancy has no effect on later autism diagnoses in children. The research, which utilized Denmark's robust national healthcare system to track more than 1.5 million children born between 1997 and 2022, including 31,098 children who were exposed to Tylenol in utero, found no significant link between Tylenol use and autism. The study's findings contradict claims made by the Trump administration, which had suggested that Tylenol use during pregnancy was a major cause of autism in children. This led to a notable 16% drop in Tylenol orders for pregnant women in emergency rooms following the announcement. However, the new study provides reassurance that Tylenol is safe to use during pregnancy for pain relief and fever reduction. According to the study, autism was diagnosed in 1.8% of children who were exposed to Tylenol and 3% of those who weren’t. A similar 2024 study in Sweden found a marginal link that disappeared after considering siblings, suggesting that autism is strongly genetic. Health officials had previously announced a label change for acetaminophen, warning of a potential link to autism, which has now been called into question. Experts, such as Jeremy Faust, an emergency physician at Mass General Brigham and a health services researcher at Harvard Medical School, have noted that the words of health officials can significantly affect behavior, as evidenced by the drop in Tylenol orders. However, Faust also emphasized that Tylenol remains one of the safest options for pain control and fever reduction during pregnancy.

More than 1,000 film and television professionals have signed an open letter opposing Paramount’s pending acquisition of Warner Bros Discovery, a deal valued at $111 billion. The signatories include high‑profile names such as Joaquin Phoenix, Ben Stiller, Mark Ruffalo, Yorgos Lanthimos, Kristen Stewart, Jane Fonda, and Emma Thompson.The letter, published on BlocktheMerger.com, warns that the merger would undermine the integrity, independence and diversity of the U.S. media sector, consolidating the number of major studios to just four and jeopardising a "vibrant future" for what it calls America’s "single most significant export" – its cultural content.Signatories argue that media consolidation already weakens competition, leading to fewer mid‑budget films, reduced independent distribution, higher production costs and fewer jobs across the ecosystem. They stress that competition is essential for both a healthy economy and a healthy democracy.Among the notable supporters are directors Denis Villeneuve, Boots Riley, Mimi Leder and Nicole Holofcener, as well as TV veterans David Chase, Noah Wyle, Ramy Youssef, Rob Delaney, Jason Bateman and Ted Danson. The letter also praises California Attorney General Rob Bonta and other state officials for scrutinising the deal.Paramount CEO David Ellison, who outbid Netflix for Warner Bros, claims the merger will boost creative output, pledging to release 30 theatrical titles annually and invest in both studios. Critics, however, remain skeptical, pointing to the Ellisons’ political ties and the risk of fewer politically‑engaged films.Recent accolades underscore the stakes: Warner Bros productions captured a record 11 Oscars in March, while Paramount films earned no nominations. The industry fears that the combined entity could further diminish quality and lead to significant job losses.Paramount has responded with a statement emphasizing that the transaction will “create a company that can greenlight more projects, back bold ideas, support talent across multiple stages of their careers, and bring stories to audiences at a truly global scale—while strengthening competition.” The letter’s authors remain unconvinced, urging regulators to block the merger to preserve competition, protect jobs, and safeguard the cultural export that defines American cinema.

Tucker Carlson, the former Fox News host, is set to launch his own publishing imprint, Tucker Carlson Books, in partnership with US-based publisher Skyhorse. The imprint aims to provide a platform for books that might otherwise be censored or shut down.Among the initial titles to be published are Russell Brand's How to Become a Christian in Seven Days, described as a "testimony and guide to a timeless, yet zeitgeist-capturing, grounded, yet psychedelic encounter with Christ." Brand is currently facing charges of rape, sexual assault, and indecent assault in the UK, to which he has pleaded not guilty.Another title set to be published is Milo Yiannopoulos's Ex Gay. Yiannopoulos, a controversial "alt-right" commentator, has previously been shunned by publishers due to his contentious views. His 2017 memoir, Dangerous, was canceled by Simon & Schuster after footage surfaced in which he made comments that appeared to condone sex between adult men and underage boys.Carlson, a former Trump supporter and promoter of right-wing conspiracy theories, was reportedly fired from Fox News in 2023. He soon launched his own media company, Tucker Carlson Network, and the imprint is being launched in partnership with this network.Skyhorse publisher Tony Lyons stated that the imprint will give "a platform to things that would, in many cases, be shut down, be censored, and be covered over by propaganda." Carlson emphasized that Lyons is "just looking for books that nobody else will publish."Skyhorse, which was launched in 2006, claims to be one of the fastest-growing independent book publishers in the US. Its previous publications include Woody Allen's memoir Apropos of Nothing and US Secretary of Health and anti-vaccine activist Robert F Kennedy Jr's The Real Anthony Fauci.

Conversations about mundane topics are often dreaded, but research suggests that people enjoy them more than they anticipate. A study involving 1,800 volunteers found that participants enjoyed chatting about dull subjects, such as the stock market or vegan diets, more than they expected. The findings indicate that by avoiding potentially dull exchanges, individuals may miss out on the mood boost and health benefits that come with connecting with others. Elizabeth Trinh, a PhD candidate in management and organisations at the University of Michigan, noted that people tend to underestimate how interesting and enjoyable conversations about boring topics can be. Trinh and her colleagues conducted a series of experiments to gauge how people responded to conversations on dull topics. Participants were asked to predict how much they would enjoy discussing topics they considered boring, and then engage in brief conversations about those topics. The results, published in the Journal of Personality and Social Psychology, showed that people consistently found the conversations more enjoyable than they expected. The surprise enjoyment arises because individuals base their expectations on static components, such as the topic and the other person, rather than dynamic components, like the conversation itself. Trinh suggests that people may benefit from lowering the bar for what makes a conversation worth having and reframing conversational goals. Instead of focusing on enjoyment, individuals could think about what they might learn from the conversation. Nicholas Epley, a professor of behavioural science at the University of Chicago, added that the fear of a boring conversation shouldn’t prevent people from starting one. “If a conversation is boring once you’re in it, you also have a surprising amount of power to make it better!”

Scientists at London's Institute of Cancer Research and the RCSI University of Medicine and Health Sciences in Dublin have announced a new AI-driven approach to identify how patients with advanced bowel cancer will respond to bevacizumab, a drug recently introduced by the NHS. The method uses PhenMap, an AI tool that integrates complex data on the genetic makeup of tumors, allowing researchers to track patterns of how different patients react to the drug. This development aims to spare potentially thousands of patients from being given drugs that would be ineffective in fighting their cancers. In the UK alone, nearly 10,000 cases of advanced bowel cancer are identified every year, with young adults seeing a particular rise in diagnoses. Bowel cancer has the second-highest mortality rate of any cancer, behind only lung cancer. While survival rates can be as high as 98% when caught early, the five-year survival rate for advanced bowel cancer can be as low as 10%. The study tracked 117 European bowel cancer patients who had been treated with chemotherapy and bevacizumab. Researchers identified a group of patients who all had the same gene mutation and were at a high risk of having negative reactions. The scientists behind the tests now hope to expand the number of patient samples and see if the results can be used in treatments for other types of cancer. Anguraj Sadanandam, a professor in stratification and precision medicine at the ICR, said: “Once bowel cancer spreads to other parts of the body, there are very few treatment options available for patients. It is therefore positive that patients can now access the targeted drug bevacizumab on the NHS. However, we know that the majority of patients won’t benefit from the drug, meaning thousands of people in England could be facing unpleasant side effects unnecessarily.” Sadanandam added that while the findings were encouraging, the tool would need to be tested on a larger cohort to be validated. “In future, I hope this approach will lead to a test that can be used by clinicians, to ensure patients receive personalised care that has the highest chance of working against their cancer.”